

# Q3 2018 FINANCIAL RESULTS SALES WORLDWIDE

**\$7.7**  
billion

**+7.8%**<sup>1</sup>  
on organic basis\*

## STRONG PERFORMANCE IN CORE BUSINESS SEGMENTS<sup>1</sup>

Sales on organic basis\*

### DIAGNOSTICS



**+7.5%**

### MEDICAL DEVICES



**+9.8%**

### NUTRITION



**+6.1%**

### ESTABLISHED PHARMACEUTICALS



**+5.9%**

## FULL-YEAR 2018 GUIDANCE NARROWED

\$2.87 TO \$2.89 ADJUSTED EPS, REFLECTING 15% GROWTH.<sup>2</sup>

## HELPING PEOPLE LIVE FULLY WITH LIFE-CHANGING TECHNOLOGY

### PRODUCT DEVELOPMENTS



- **FreeStyle® Libre 14 day system**, the longest lasting self-applied glucose sensor available, approved in the U.S.
- **FreeStyle® Libre 2 system**, a next-generation product utilizing Bluetooth technology and offering optional real-time glucose alarms, received CE Mark in Europe<sup>3</sup>
- **MitraClip® NTR** and **MitraClip® XTR**, the latest versions of our leading heart valve repair device, approved in the U.S.
- **High Sensitive Troponin-I**, a test to help predict the chances of a heart attack potentially up to months to years in advance, available in Europe
- Positive results from the landmark COAPT trial demonstrated **MitraClip** improved survival and clinical outcomes for select patients with secondary mitral regurgitation (leaky heart valve); data expected to support an expanded indication for MitraClip

\*Organic sales growth: Excludes prior year results for the Abbott Medical Optics (AMO) and St. Jude Medical vascular closure businesses, which were divested during the first quarter 2017; Excludes the current and prior year results for Rapid Diagnostics, which reflect results for Alere Inc., which was acquired on Oct. 3, 2017; and Excludes the impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated October 17, 2018. <sup>1</sup>On a GAAP basis, Abbott sales increased 12.1%; Diagnostics sales increased 42.6%; Medical Devices sales increased 8.4%; Nutrition sales increased 4.0%; and Established Pharmaceuticals sales decreased 0.9%. <sup>2</sup>Full-year 2018 GAAP EPS guidance of \$1.33 to \$1.35, 570% growth. <sup>3</sup>Not available in the United States.

#### FORWARD-LOOKING STATEMENTS

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2017, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.